Comparing two surgical methods for treating secondary hyperparathyroidism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares the long-term outcomes of total parathyroidectomy with autotransplantation (TPTX+AT) versus total parathyroidectomy alone (TPTX) in patients with secondary hyperparathyroidism who are on long-term dialysis. It is a randomized controlled pilot trial involving 200 patients, aiming to assess the rates of recurrent disease over a 5-year follow-up period. Key metrics evaluated include parathyroid hormone and calcium levels, as well as rates of recurrent or persistent hyperparathyroidism, reoperations, morbidity, and mortality.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Severe renal secondary hyperparathyroidism

Exclusion Criteria:

Patients with diabetes a history of chronic inflammatory disease a history of malignant tumor a history of kidney transplantation a history of neck surgery a history of alcohol abuse a history of drug abuse inability to cooperate with the participants refusal to participate in the study

Where it's running

• NanjingMU
  Nanjing, China Recruiting

Study contacts

• Study coordinator: Mingxia XIONG, Ph.D
• Email: xiongmingxia@njmu.edu.cn
• Phone: 13951880995

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CTAP101 extended-release capsules in kids with CKD and vitamin D insufficiency

  A daily bedtime dose of CTAP101 is being tested in children with CKD stages 3–4 and secondary hyperparathyroidism to see how the drug moves in the body, how it affects the body, and whether it is safe and tolerable.

  Recruiting Phase 2 OPKO Health, Inc. · Kansas City, Missouri and 4 other locations · NCT07494045

• Evaluating the effects of Pacitol Inj. on patients with chronic kidney disease and secondary hyperparathyroidism

  This study is testing if a new injection called Pacitol can help people with severe kidney disease and high parathyroid hormone levels feel better while they are on dialysis.

  Recruiting Boryung Pharmaceutical Co., Ltd · Goyang-si, Gyeonggi-do · NCT06126016

• Using microRNA to improve treatment for renal osteodystrophy

  This study is testing if a new method using microRNA can help doctors better understand bone health in people with chronic kidney disease and improve their treatment for renal osteodystrophy.

  Recruiting Washington University School of Medicine · St Louis, Missouri · NCT05880914

• Treatment of secondary hyperparathyroidism in children on hemodialysis

  This study tests if a new medication called etelcalcetide can help children on hemodialysis lower their parathyroid hormone levels safely.

  Recruiting at 10 sites Phase 3 Amgen · Ghent and 22 other locations · NCT03969329

• Etelcalcetide treatment for children with kidney disease and high parathyroid hormone levels

  This study is testing if a new treatment called Etelcalcetide can help children with kidney disease and high parathyroid hormone levels feel better and avoid serious health problems.

  Recruiting at 19 sites Phase 3 Amgen · Los Angeles, California and 42 other locations · NCT03633708

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.